A vaccine designed to prevent human cytomegalovirus elicited long-lasting immune responses.

Wednesday, February 21, 2024 Novel CMV Vaccine Generates Stronger Response in Key Immune Cells Than Previous Candidate Transmission electron micrograph of cytomegalovirus particles (burgundy) found within intracellular vesicles of an infected macrophage (green). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID A messenger RNA (mRNA) vaccine designed to prevent human cytomegalovirus (CMV) elicited long-lasting CMV-specific responses from several types of immune cells, outperforming a previous vaccine concept in multiple measures in a NIAID-supported laboratory study. The findings were published in the Journal of Infectious Diseases. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107